People often ask me what are the most promising stem cell therapies in development and new data suggest we should add stem cells for epilepsy to the list based on work by Neurona Therapeutics. I’ll start off the weekly recommended reads with this new mouse paper on cell therapy for epilepsy. Neurona Therapeutics: stem cells …
Where do things stand with the investigative approach of stem cells for diabetes? 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells, Medscape. Not the best headline given the few number of participants here. If your study has only two subjects and one responds, someone is going to say, “50% of people had a …
Weekly reads: Vertex stem cells for diabetes update, new CRISPR , immortality Read More »
A team led by Harvard professor David Sinclair had a recent Cell paper on reprogramming to fight aging that I reviewed here on The Niche. I thought the paper was exciting and important. Note that in vivo reprogramming was first done more than a decade ago. Sinclair did have a novel fast-forward aging method and overall …
Weekly reads: oocytes from males, David Sinclair longevity inc, diabetes, He Jiankui Read More »
I took a cross-country road trip earlier this month that was pretty amazing and barely thought about stem cell research for the first time in years. We did run across one stem cell clinic in Florida by accident. I’ll write about that trip soon, but first we have our weekly reads including some very cool …
Weekly stem cell reads: space, plagiarism, HIV, diabetes, more Read More »
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
The past year was all over the place for the stem cell and regenerative medicine field. As you can see in my scoring of my 21 predictions for 2021, quite a few things were surprises in terms of what did and didn’t happen. Here’s an overview of the top stories of the year in our …
Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court Read More »
The amount of biomedical science hype out there is mindboggling at times, but some media or other items really take the cake for being exceptionally bad. Today’s post highlights the worst of the year 2021 as the candidates for my annual The Screamers science hype award. Click on the link in the previous sentence to …
Part of being a grad student is dealing with technologies related to your projects and their limitations. Sometimes I feel old when I remember the way we used to have to do things in the lab. As a grad student, I manually poured, ran, and read giant sequencing gels. Back then, gene synthesis of a …
Weekly reads: grad student life, cell barcoding, diabetes trial, more Read More »
If you celebrate the Thanksgiving holiday I hope you had a nice one and, right before it started a new article popped on the scene about the CRISPR babies. Before we discuss those three gene-edited people, who are now growing up into little kids, we hit a milestone on our YouTube Stem Cell Channel with …
Regenerative reads: 3 CRISPR babies, FDA warning, diabetes, pubs Read More »
It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This …
Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »